Biosafety of Adenoviral Vectors
Abstract
Adenoviral vectors can efficiently transduce a broad variety of different cell types and have been used extensively in preclinical and clinical studies. However, early generation of adenoviral vectors retained residual adenoviral genes that contribute to inflammatory immune responses and toxicity. In addition, these vectors often result in transient expression of the potentially therapeutic transgene. Some clinical trials based on early generation adenoviral vectors have been discontinued because of acute inflammatory responses and toxicity and even one patient has died as a direct consequence of adenoviral toxicity. The latest generation of highcapacity adenoviral vectors is devoid of viral genes, and is having a significantly improved safety profile and yielding more prolonged transgene expression compared to early generation vectors. Nevertheless, transgene expression gradually declines even when high-capacity adenoviral vectors are used, possibly due to the gradual loss of vector genomes. Despite their improved safety, high-capacity adenoviral vectors can still trigger transient toxic effects in animals and patients. Restricting the tropism of adenoviral vectors by immunologic or genetic retargeting may further improve their therapeutic window. The safety of adenoviral vectors has been improved further through the development of safer packaging systems that eliminate the homologous overlap between vector and helper sequences and therefore prevent formation of replication-competent adenoviruses (RCA). RCA could exacerbate inflammatory responses and act as a helper to rescue adenoviral vectors, potentially increasing the effective vector dose. Conditionally replicating adenoviruses (CRAds) have been developed for cancer gene therapy, which replicate selectively in some cancer cells. The use of CRAds in combination with chemotherapy yielded therapeutic effects in patients suffering from cancer but dose-limiting toxicity was apparent. Although there appears to be a very low theoretical risk of malignancy that is predominately associated with the occurrence of E1-positive recombinants, no malignancies have been reported that were associated with adenoviral vectors. Nevertheless, integrating adenoviral vectors carry a greater malignancy risk due to their ability to integrate randomly into the target genomes.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The typical feature of RV and retroviral vectors is their ability to integrate into host DNA.
“The typical feature of RV and retroviral vectors is their ability to integrate into host DNA.”
From Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges (2020) · cites this paper as [78]
Cited by
Sorted by citations
Physical methods for gene transfer: Improving the kinetics of gene delivery into cells
Mehier-Humbert, S., & Guy, R. H. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.12.007 · Cited by 396 · see citing works
Ghosh, S., Brown, A. M., Jenkins, C., & Campbell, K. (2020) · Applied Biosafety · doi:10.1177/1535676019899502 · Cited by 218 · see citing works
“The typical feature of RV and retroviral vectors is their ability to integrate into host DNA.(78) Besides, complex RV such as HIV-1 encode accessory proteins that enhance replication and infectivity.”
BackgroundMethodInfluentialRincón, M. Y., VandenDriessche, T., & Chuah, M. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv205 · Cited by 168 · see citing works
“hepatocytes, antigen-presenting cells).(33) Consequently, the utility of Ad vectors in cardiovascular gene therapy trials in humans must be carefully evaluated.”
BackgroundSelf-citationAntiadenovirus Activities of Several Classes of Nucleoside and Nucleotide Analogues
Naesens, L. M. J., Lenaerts, L., Andreï, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.1010-1016.2005 · Cited by 156 · see citing works
“Another interesting implication from our studies in HSV-1 TK osteosarcoma cells concerns the potential usefulness of ganciclovir in the context of gene therapy using adenovirus vectors with limited replication capacity (5).”
BackgroundMatsui, M., & Tabata, Y. (2012) · Acta Biomaterialia · doi:10.1016/j.actbio.2012.01.016 · Cited by 148 · see citing works
“On the other hand, the biosafety of genetic materials is not always confirmed [1-3].”
BackgroundAdvanced physical techniques for gene delivery based on membrane perforation
Du, X., Wang, J., Zhou, Q., Zhang, L., Wang, S., Zhang, Z., & Yao, C. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1480674 · Cited by 147 · see citing works
“But it has potentially risk that viral vectors may infect healthy cell adjacent to the target cell (Moss, 2014), even can lead to patient death because of inflammatory immune responses induced by adenoviral vectors (Chuah et al., 2003), and the size of genetic materials inserted into cell is limited (ElAneed, 2004; Lv…”
BackgroundDirect Percutaneous Gene Delivery to Enhance Healing of Segmental Bone Defects
Betz, O. B., Betz, V. M., Nazarian, A., et al. (2006) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.e.00464 · Cited by 125 · see citing works
Li, J., Liu, H., Xr, Z., Xu, J.-P., Hu, W.-K., Liang, M., Chen, S.-Y., Hu, F., & Chu, D.-T. (2008) · Gene Therapy · doi:10.1038/gt.2008.179 · Cited by 118 · see citing works
Meacham, J., Durvasula, K., Degertekin, F., & Fedorov, A. G. (2013) · Journal of laboratory automation · doi:10.1177/2211068213494388 · Cited by 104 · see citing works
“Adenoviral vectors have induced inflammatory immune responses and toxicity leading to patient death.(13) Retroviral vectors carry the risks of transmission of replication-competent virus(14) and, more Figure 1.”
BackgroundSignaling cascades in the failing heart and emerging therapeutic strategies
He, X., Du, T., Long, T., Liao, X., Dong, Y., & Huang, Z. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00972-6 · Cited by 105 · see citing works
“Moreover, transfection of the Ad vector into nontarget cells was also a potential problem in cardiac gene therapy.(461) To solve the problem of specificity, an adenovirus serotype 5 (Ad5)-derived recombinant vector was used as gene therapy for cardiac disease.”
MethodRádis‐Baptista, G., Campelo, I. S., Morlighem, J.-É. R. L., Melo, L. M., & Freitas, V. J. D. F. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.05.002 · Cited by 91 · see citing works
Meyer, S. D. D., Vanhoorelbeke, K., Chuah, M., Pareyn, I., Gillijns, V., Hebbel, R., Collen, D., Deckmyn, H., & VandenDriessche, T. (2006) · Blood · doi:10.1182/blood-2005-09-3605 · Cited by 91 · see citing works
Self-citationNanoparticle-mediated gene delivery: state of the art
Kumar, M., Hellermann, G., Lockey, R. F., & Mohapatra, S. S. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.8.1213 · Cited by 82 · see citing works
“Although viral vectors yield high transfection efficiency in a wide range of cells [2,3], they may cause inflammation and even cancer through incorporation of DNA into the host genome [4].”
BackgroundPolymer Nanoneedle‐Mediated Intracellular Drug Delivery
Kolhar, P., Doshi, N., & Mitragotri, S. (2011) · Small · doi:10.1002/smll.201100497 · Cited by 81 · see citing works
Microfluidic approaches for gene delivery and gene therapy
Kim, J., Hwang, I., Britain, D., et al. (2011) · Lab on a Chip · doi:10.1039/c1lc20766k · Cited by 73 · see citing works
Gao, K., Li, L., He, L., et al. (2013) · Small · doi:10.1002/smll.201300116 · Cited by 58 · see citing works
Evolving gene therapy approaches for osteosarcoma using viral vectors: review.
Witlox, M., Lamfers, M., Wuisman, P., Curiel, D. T., & Siegal, G. P. (2007) · Bone · doi:10.1016/j.bone.2006.10.017 · Cited by 59 · see citing works
“In close relation to safety issues is the activation of innate immunity to some of the vectors described above (20).”
BackgroundInfluentialArtificial envelopment of nonenveloped viruses: enhancing adenovirus tumor targeting in vivo
Singh, R. N., Tian, B., & Kostarelos, K. (2008) · The FASEB Journal · doi:10.1096/fj.08-103275 · Cited by 47 · see citing works
“Unfortunately, Ad is rapidly cleared from circulation by the MPS (8), with a blood half-life in mice of less than 2 min (10), and readily infects the liver and spleen, leading to severe hepatotoxicity at high doses (47, 48).”
BackgroundHigh Transduction Efficiency of Human Amniotic Fluid Stem Cells Mediated by Adenovirus Vectors
Grisafi, D., Piccoli, M., Pozzobon, M., et al. (2008) · Stem Cells and Development · doi:10.1089/scd.2007.0188 · Cited by 45 · see citing works
Han, G., Li, Y., Wang, J., Wang, R., Chen, G., Song, L., Xu, R., Yu, M., Wu, X., Qian, J., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4516 · Cited by 45 · see citing works
“First, unlike retroviral or adenovirus vectors, AAV-mediated vector integration is relatively uncommon (31).”
BackgroundKerkis, I., Silva, F. D. S., Pereira, A. G., Kerkis, A., & Rádis‐Baptista, G. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.534457 · Cited by 45 · see citing works
“Additionally, they potentially cause undesirable immune responses [64].”
BackgroundViral Vector Biosafety in Laboratory Animal Research.
Collins, D. E., Reuter, J. D., Rush, H. G., et al. (2017) · PubMed · Cited by 42 · see citing works
Nakamura, A. (2019) · Journal of Personalized Medicine · doi:10.3390/jpm9010016 · Cited by 41 · see citing works
“The latest generation of high-capacity adenoviral vectors is devoid of viral genes, has a significantly improved safety profile, and yields prolonged transgene expression compared with that of early generation vectors [79].”
BackgroundInfluentialConstruction and characterization of adenoviral vectors for the delivery of TALENs into human cells
Holkers, M., Cathomen, T., & Gonçalves, M. A. F. V. (2014) · Methods · doi:10.1016/j.ymeth.2014.02.017 · Cited by 34 · see citing works
Spaner, D., Hammond, C., Mena, J., et al. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0626-5 · Cited by 32 · see citing works
“generally available and can be cumbersome, inefficient, expensive, and even dangerous [12].”
Anticancer vaccination strategies
Nencioni, A., Grünebach, F., Patrone, F., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh920 · Cited by 28 · see citing works
“Another concern related to this kind of approach is represented by the safety issues, given that in some studies heavy side-effects have been associated with virus administration [47].”
BackgroundCell Culture Processes for the Production of Viral Vectors for Gene Therapy Purposes
Warnock, J. N., Merten, O., & Al‐Rubeai, M. (2006) · Cytotechnology · doi:10.1007/s10616-005-5507-z · Cited by 28 · see citing works
“Expression of E1A initiates adenoviral replication and activates adenoviral transcription (Chuah et al. 2003); therefore, an adenovirustransformed cell line that provides the missing E1A and E1B genes in trans is required to grow the replication defective virus (Graham et al.”
BackgroundDIRECT PERCUTANEOUS GENE DELIVERY TO ENHANCE HEALING OF SEGMENTAL BONE DEFECTS
Betz, O. B., Betz, V. M., Nazarian, A., et al. (2006) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-200602000-00015 · Cited by 27 · see citing works
Senevirathne, A., Park, J.-Y., Hewawaduge, C., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121226 · Cited by 23 · see citing works
Effect of Varying Magnetic Fields on Targeted Gene Delivery of Nucleic Acid-Based Molecules
Oral, Ö., Çıkım, T. A., Zuvin, M., et al. (2015) · Annals of Biomedical Engineering · doi:10.1007/s10439-015-1331-6 · Cited by 18 · see citing works
Gene delivery to pancreatic exocrine cells in vivo and in vitro
Houbracken, I., Baeyens, L., Ravassard, P., Heimberg, H., & Bouwens, L. (2012) · BMC Biotechnology · doi:10.1186/1472-6750-12-74 · Cited by 17 · see citing works
“Furthermore, acute direct toxicity of adenoviral proteins has been described [65,66].”
Gene Therapy - Developments and Future Perspectives
Kang, C. (2011) · InTech eBooks · doi:10.5772/748 · Cited by 16 · see citing works
Gene Therapy of Chronic Limb-Threatening Ischemia: Vascular Medical Perspectives
Simon, F., Duran, M., Garabet, W., Schelzig, H., Jacobs, M. J. H. M., & Gombert, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051282 · Cited by 16 · see citing works
Liu, J., Ma, X., Guo, W., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113026 · Cited by 12 · see citing works
A replication-competent adenovirus assay for E1-deleted Ad35 vectors produced in PER.C6 cells
Marzio, G., Kerkvliet, E., Bogaards, J. A., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.12.011 · Cited by 12 · see citing works
Huang, N.-C., Lee, C., & Hsu, S. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2019.12.003 · Cited by 12 · see citing works
Martina, Y., Avitabile, D., Piersanti, S., Cherubini, G., & Saggio, I. (2007) · Virus Research · doi:10.1016/j.virusres.2007.05.019 · Cited by 12 · see citing works
Regulated expression of sFRP-1 protein by the GeneSwitch system
Bhat, R. A., Stauffer, B., Komm, B. S., et al. (2004) · Protein Expression and Purification · doi:10.1016/j.pep.2004.06.029 · Cited by 12 · see citing works
Biosafety and Viral Gene Transfer Vectors
Kost, T. A., Patrick, C. J., & Mickelson, C. A. (2014) · ASM Press eBooks · doi:10.1128/9781555815899.ch28 · Cited by 10 · see citing works
Balaji, S., Zhou, Y., Opara, E. C., et al. (2017) · Cellular Reprogramming · doi:10.1089/cell.2016.0043 · Cited by 9 · see citing works
“Furthermore, while an adenoviral approach may not be well suited for in vivo transplant experiments due to their elevated immune potential (Chuah et al., 2003), this work has shown conclusively that turning on the master regulator of pancreatic development can indeed drive multiprogenitor cells from tissues as diverse…”
Synthetic Receptor-Based Targeting Strategies to Improve Tumor Drug Delivery
Nethi, S. K., Bhatnagar, S., & Prabha, S. (2021) · AAPS PharmSciTech · doi:10.1208/s12249-021-01919-w · Cited by 8 · see citing works
Nakamura, A., Imaizumi, A., Niimi, R., et al. (2005) · Clinical Science · doi:10.1042/cs20050088 · Cited by 8 · see citing works
Gene therapy techniques: Physical and chemical methods
Attar, A. (2017) · Turkish Bulletin of Hygiene and Experimental Biology · doi:10.5505/turkhijyen.2016.43255 · Cited by 7 · see citing works
“Proc Assoc Am Physicians, 1996; 108 (2): 165-72.”
Cells for Gene Therapy and Vector Production
Delenda, C., Chillón, M., Douar, A. M., & Merten, O. (2007) · Methods in biotechnology · doi:10.1007/978-1-59745-399-8_2 · Cited by 7 · see citing works
Stability of Viral Pathogens in the Laboratory Environment
Valtierra, H. N. (2008) · Applied Biosafety · doi:10.1177/153567600801300104 · Cited by 6 · see citing works
“Adenoviruses and their cognate vectors differ in that the parental virus can cause a productive infection associated with viral replication, whereas adenoviral vectors are replication impaired (Chuah et al., 2003).”
BackgroundMouse In Vivo Placental Targeted CRISPR Manipulation
Carver, A. J., Taylor, R. J., & Stevens, H. E. (2023) · Journal of Visualized Experiments · doi:10.3791/64760 · Cited by 5 · see citing works
Nanosecond laser pulse induced stress waves enhanced magnetofection of human carcinoma cellsin vitro
Durdík, Š., Babincová, M., Bergemann, C., et al. (2012) · Laser Physics Letters · doi:10.7452/lapl.201210064 · Cited by 5 · see citing works
Efficacy of Gene Transfer through the Round Window Membrane: An in vitro Model
Aarnisalo, A. A., Aarnisalo, P., Pietola, L., et al. (2006) · ORL · doi:10.1159/000092123 · Cited by 5 · see citing works
Senevirathne, A., Hewawaduge, C., & Lee, J. H. (2021) · Veterinary Research · doi:10.1186/s13567-021-00995-x · Cited by 5 · see citing works
“Although viral vectors are widely used [4] for delivery of the CRISPR/Cas9 system in vitro and in vivo, their fundamental shortcomings, such as the risk of carcinogenesis, limited insertion size, immune response induction, difficulty in large-scale production, genomic manipulation issues, and narrow tissue tropism, im…”
BackgroundMethods of gene delivery and perspectives of their application in the gene therapy
Apartsin, E. K., & Knauer, N. (2016) · Genes and Cells · doi:10.23868/gc120566 · Cited by 4 · see citing works
Advances in Oncolytic Virotherapy for Brain Tumors
Balvers, R. K., Gomez‐Manzano, C., Jiang, H., et al. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394295-1.00010-x · Cited by 4 · see citing works
“Adenoviruses have long been used to deliver genes and are generally considered to be safe [4], easy to genetically manipulate [5], and researchers are capable of generating”
MethodSystemic IL-12 Gene Therapy for Treating Malignancy via Intramuscular Electroporation
Zhu, S., & Li, S. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-194-9_25 · Cited by 4 · see citing works
Ghosh, S., Blind, J. E., Fowler, A. M., Parsons, S., Nelson, K. L., & Campbell, K. (2025) · Applied Biosafety · doi:10.1089/apb.2024.0057 · Cited by 3 · see citing works
Izadi, E., Mohammadi, S. S., Ganjalıkhani-Hakemi, M., Eshghi, S., Saremi, L., Saltanatpour, Z., & Hamidieh, A. A. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177786 · Cited by 4 · see citing works
Krewet, J. A., Ren, W., Huang, X. F., et al. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0683-4 · Cited by 3 · see citing works
“in both animal and human studies is well documented [11] .”
BackgroundMethodAdenovirus as Tools in Animal Health
Rojas, J. M., Sevilla, N., & Martı́n, V. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.79132 · Cited by 5 · see citing works
“The RDAd used as vectors can be divided into three classes, schematized in Figure 1B [7, 8], according to the size of the deletions made in their genome, which directly impacts on the size of the exogenous DNA they can harbor.”
BackgroundRecent Advances and Improvements in the Biosafety of Gene Therapy
Sivalingam, J., & Lian, O. (2011) · InTech eBooks · doi:10.5772/21733 · Cited by 2 · see citing works
“, 2003), replication competent adenovirus (Chuah et al., 2003) and replication competent retrovirus (Sinn et al.”
BackgroundTomar, N. R., Vennela, A. T., Mukhopadhyay, S., & Kondapi, A. K. (2026) · Nanomedicine · doi:10.1080/17435889.2026.2634274 · Cited by 1 · see citing works
Gene therapy approaches to the duchenne muscular dystrophy theatment
Zaynitdinova, M. I., Smirnikhina, S. A., Lavrov, A. V., Eremin, I. I., & Pulin, A. A. (2019) · Genes and Cells · doi:10.23868/201912026 · Cited by 1 · see citing works
Spaner, D., Hammond, C., Mena, J., et al. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0623-8 · Cited by 1 · see citing works
Nikbakht, M. R., Murtomäki, L. S., Urtti, A. O., et al. (2013) · Pharmaceutical Sciences
Armstrong, L. (2011) · University of Minnesota Digital Conservancy (University of Minnesota)
Characterisation of a dominant negative androgen receptor in prostate cancer cells.
Centenera, M. M. (2008) · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
TBHEB 2017-1 Vol 74 Full Printed Journal
Ercömart, U. (2017) · Turkish Bulletin of Hygiene and Experimental Biology · doi:10.5505/turkhijyen.2016.21548
Roman, T. S. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/8r6k-hr09
Gene Therapy in Hereditary Diseases
Yücel, İ., & Binici, M. (2024) · Gene Therapy · doi:10.69860/nobel.9786053358824.9
Gen terapiyasinin əsas xüsusiyyətləri
Həmidova, M. (2025) · SCIENTIFIC WORK · doi:10.36719/2663-4619/115/291-294
Senevirathne, A., Hewawaduge, C., & Lee, J. H. (2021) · Figshare · doi:10.6084/m9.figshare.16713947
- Authors
- Chuah, M. K. L., Collen, D., & VandenDriessche, T.
- Affiliations
- KU Leuven (BE)
- Corresponding author
- VandenDriessche, Thierry
- Venue
- Current Gene Therapy
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2003-12
- Volume
- 3
- Issue
- 6
- Pages
- 527-543
- ISSN
- 1566-5232 (ISSN-L)
- OpenAlex
- W2157973272
- Cited by
- 71
- References
- 0
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 4 · 2020: 2 · 2019: 5 · 2018: 1 · 2017: 5 · 2016: 1 · 2015: 2 · 2014: 2 · 2013: 4 · 2012: 3
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Gene Therapy (publishedVersion)
- PubMed (publishedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- adenoviral vector, biosafety, inflammatory immune response, vector toxicity, transgene expression, cancer gene therapy, vector integration
- MeSH terms
- Adenoviridae, Animals, Female, Genetic Vectors, Safety Management, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
